UPDATE: Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 11c; Encore 601 Refractory Melanoma Cohort to Proceed to Second Stage of Phase 2

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. NAVN
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to UPDATE: Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 11c; Encore 601 Refractory Melanoma Cohort to Proceed to Second Stage of Phase 2
(NASDAQ: SNDX) Delayed: 19.32 --0 (-0%)
Previous Close $19.32    52 Week High $18.03 
Open $19.32    52 Week Low $8.97 
Day High $19.32    P/E N/A 
Day Low $19.32    EPS $0.00 
Volume 100